Application of mesenchymal stem cells in melanoma: A potential therapeutic strategy for delivery of targeted agents

Current Medicinal Chemistry

Volumn 23, Issue 5, 2016, Pages 455-463

  Mirzaei, Hamed ^a   Sahebkar, Amirhossein ^a   Avan, Amir ^a   Jaafari, Mahmoud R ^a   Salehi, Rasoul ^b   Salehi, Hossein ^b   Baharvand, Hossein ^c   Rezaei, Abbas ^b   Hadjati, Jamshid ^d   Pawelek, John M ^e   Mirzaei, Hamid R ^d  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e YALE CANCER CENTER   (United States)

Author keywords

Chemo resistance; Malignant tumor; Melanoma; Mesenchymal stem cells; Targeted anticancer therapies

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA INTERFERON; CYTOSINE DEAMINASE; GAMMA INTERFERON; PIGMENT EPITHELIUM DERIVED FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; CYTOKINE; DRUG CARRIER;

ADIPOSE DERIVED STEM CELL; ARTICLE; BIOLOGICAL ACTIVITY; CELL HOMING; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; INTRACELLULAR SIGNALING; MELANOMA; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; BIOLOGICAL THERAPY; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PROCEDURES;

CELL- AND TISSUE-BASED THERAPY; CYTOKINES; DRUG CARRIERS; HUMANS; MELANOMA; MESENCHYMAL STROMAL CELLS;

EID: 84960112251     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867323666151217122033     Document Type: Article

References (96)

1. Miller, A.J.; Mihm Jr., M.C. Melanoma. N. Engl. J. Med., 2006, 355(1), 51-65.
2. American Cancer Society. Explore Research. Cancer Facts & Figures 2012. http://www.cancer.org/research/cancer-factsstatistics/cancerfactsfigures2012/
3. Pittenger, M.F.; Mackay, A.M.; Beck, S.C.; Jaiswal, R.K.; Douglas, R.; Mosca, J.D.; Moorman, M.A.; Simonetti, D.W.; Craig, S.; Marshak, D.R. Multilineage potential of adult human mesenchymal stem cells. Science, 1999, 284(5411), 143-147.
4. Barry, F.P.; Murphy, J.M. Mesenchymal stem cells: clinical applications and biological characterization. Int. J. Biochem., 2004, 36(4), 568-584.
5. da Silva Meirelles, L.; Chagastelles, P.C.; Nardi, N. B. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J. Cell Sci., 2006, 119 (11), 2204-2213.
6. Ding, D.C.; Shyu, W.C.; Lin, S.Z. Mesenchymal stem cells. Cell Transplant., 2011, 20(1), 5-14.
7. Prockop, D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science, 1997, 276(5309), 71-74.
8. Sacchetti, B.; Funari, A.; Michienzi, S.; Di Cesare, S.; Piersanti, S.; Saggio, I.; Tagliafico, E.; Ferrari, S.; Robey, P.G.; Riminucci, M. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell, 2007, 131(2), 324-336.
9. Noel, D.; Djouad, F.; Jorgense, C. Regenerative medicine through mesenchymal stem cells for bone and cartilage repair. Curr. Opin. Investig. Drugs, 2002, 3(7), 1000-1004.
10. Sato, K.; Ozaki, K.; Oh, I.; Meguro, A.; Hatanaka, K.; Nagai, T.; Muroi, K.; Ozawa, K. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood, 2007, 109(1), 228-234.
11. Rasmusson, I.; Ringden, O.; Sundberg, B.; Le Blanc, K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp. Cell Res., 2005, 305(1), 33-41.
12. Krampera, M.; Glennie, S.; Dyson, J.; Scott, D.; Laylor, R.; Simpson, E.; Dazzi, F. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood, 2003, 101(9), 3722-3729.
13. Di Nicola, M.; Carlo-Stella, C; Magni, M.; Milanesi, M.; Longoni, P.D.; Matteucci, P.; Grisanti, S.; Gianni, A. M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 2002, 99(10), 3838-3843.
14. Djouad, F.; Fritz, V.; Apparailly, F.; Louis-Plence, P.; Bony, C; Sany, J.; Jorgensen, C; Noel, D. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum., 2005, 52(5), 1595-1603.
15. Zappia, E.; Casazza, S.; Pedemonte, E.; Benvenuto, F.; Bonanni, I.; Gerdoni, E.; Giunti, D.; Ceravolo, A.; Cazzanti, F.; Frassoni, F.; Mancardi, G.; Uccelli, A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood, 2005, 106(5), 1755-1761.
16. Meisel, R.; Zibert, A.; Laryea, M.; Gobel, U.; Daubener, W.; Dilloo, D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood, 2004, 103(12), 4619-4621.
17. Aggarwal, S.; Pittenger, M. F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 2005, 105(4), 1815-1822.
18. Ren, G.; Zhang, L.; Zhao, X.; Xu, G.; Zhang, Y.; Roberts, A.I.; Zhao, R.C.; Shi, Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2008, 2(2), 141-150.
19. Khakoo, A.Y.; Pati, S.; Anderson, S.A.; Reid, W.; Elshal, M.F.; Rovira, II; Nguyen, A.T.; Malide, D.; Combs, C.A.; Hall, G.; Zhang, J.; Raffeld, M.; Rogers, T.B.; Stetler-Stevenson, W.; Frank, J.A.; Reitz, M.; Finkel, T. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. JEM, 2006, 203(5), 1235-1247.
20. Nakamizo, A.; Marini, F.; Amano, T.; Khan, A.; Studeny, M.; Gumin, J.; Chen, J.; Hentschel, S.; Vecil, G.; Dembinski, J.; Andreeff, M.; Lang, F. F. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res., 2005, 65(8), 3307-3318.
21. Han, Z.; Tian, Z.; Lv, G.; Zhang, L.; Jiang, G.; Sun, K.; Wang, C; Bu, X.; Li, R.; Shi, Y.; Wu, M.; Wei, L. Immunosuppressive effect of bone marrow-derived mesenchymal stem cells in inflammatory microenvironment favours the growth of B16 melanoma cells. J. Cell Mol. Med., 2011, 15(11), 2343-2352.
22. Stuckey, D.W.; Hingtgen, S.D.; Karakas, N.; Rich, B.E.; Shah, K. Engineering toxin-resistant therapeutic stem cells to treat brain tumors. Stem Cells, 2015, 33, 589-600.
23. Mizuno, H.; Tobita, M.; Uysal, A. C. Concise review: adipose-derived stem cells as a novel tool for future regenerative medicine. Stem Cells, 2012, 30(5), 804-810.
24. Keung, E.Z.; Nelson, P.J.; Conrad, C. Concise review: genetically engineered stem cell therapy targeting angiogenesis and tumor stroma in gastrointestinal malignancy. Stem Cells, 2013, 31(2), 227-235.
25. Salem, H.K.; Thiemermann, C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells, 2010, 28(3), 585-596.
26. Wang, Z.; Wang, Y.; Wang, Z.; Gutkind, J.S.; Wang, Z.; Wang, F.; Lu, J.; Niu, G.; Teng, G.; Chen, X. Engineered mesenchymal stem cells with enhanced tropism and paracrine secretion of cytokines and growth factors to treat traumatic brain injury. Stem Cells, 2015, 33(2), 456-467.
27. Ylöstalo, J.H.; Bartosh, T.J. Mesenchymal stem cells characteristics, niches, and applications for cell therapy. Encyclopedia Mol. Cell Biol. Mol. Med., 2013; doi: 10.1002/3527600906.mcb.201200009
28. Altaner, C. Stem cell-mediated prodrug gene therapy of high-grade brain tumors. Stem Cell Ther. Cancer, 2013, 12(2), 57-71.
29. Fonsato, V.; Collino, F.; Herrera, M.B.; Cavallari, C; Deregibus, M.C.; Cisterna, B.; Bruno, S.; Romagnoli, R.; Salizzoni, M.; Tetta, C. Human liver stem cell-derived microvesicles inhibit hepatoma growth in SCID mice by delivering antitumor MicroRNAs. Stem Cells, 2012, 30(9), 1985-1998.
30. Dwyer, R. Diagnostic and therapeutic mesenchymal stem cells for breast cancer treatment. Stem Cell Ther. Cancer, 2013, 12(2), 145-158.
31. Keung, E.; Nelson, P.J.; Conrad, C. Genetically engineered stem cell therapies targeting gastrointestinal malignancy. Stem Cell Ther. Cancer, 2013, 12(2),159-170.
32. Nakamizo, A.; Marini, F.; Amano, T.; Khan, A.; Studeny, M.; Gumin, J.; Chen, J.; Hentschel, S.; Vecil, G.; Dembinski, J. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res., 2005, 65(8), 3307-3318.
33. Studeny, M.; Marini, F.C.; Dembinski, J.L.; Zompetta, C; Cabreira-Hansen, M.; Bekele, B.N.; Champlin, R.E.; Andreeff, M. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J. Natl. Cancer Inst., 2004, 96(21), 1593-1603.
34. Ben-Baruch, A. Host microenvironment in breast cancer development: Inflammatory cells, cytokines and chemokines in breast cancer progression-reciprocal tumor-microenvironment interactions. Breast Cancer Res., 2002, 5(1), 31.
35. Bissell, M.J.; Radisky, D. Putting tumours in context. Nat. Rev. Cancer, 2001, 1(1), 46-54.
36. Mimeault, M.; Batra, S. K. Concise review: recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells, 2006, 24(11), 2319-2345.
37. Vicari, A.P.; Caux, C. Chemokines in cancer. Cytokine Growth Factor Rev., 2002, 13(2), 143-154.
38. Lazennec, G.; Richmond, A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol. Med., 2010, 16(3), 133-144.
39. Loebinger, M.R.; Janes, S. M. Stem cells as vectors for antitumour therapy. Thorax, 2010, 65(4), 362-369.
40. Spaeth, E.; Klopp, A.; Dembinski, J.; Andreeff, M.; Marini, F. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther, 2008, 15(10), 730-738.
41. Ramasamy, R.; Fazekasova, H.; Lam, E. W.F.; Soeiro, I.; Lombardi, G.; Dazzi, F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation, 2007, 83(1), 71-76.
42. Ringe, J.; Strassburg, S.; Neumann, K.; Endres, M.; Notter, M.; Burmester, G.R.; Kaps, C; Sittinger, M. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J. Cell Biochem., 2007, 101(1), 135-146.
43. Stich, S.; Loch, A.; Leinhase, I.; Neumann, K.; Kaps, C; Sittinger, M.; Ringe, J. Human periosteum-derived progenitor cells express distinct chemokine receptors and migrate upon stimulation with CCL2, CCL25, CXCL8, CXCL12, and CXCL13. EJCB, 2008, 87(6), 365-376.
44. Ponte, A.L.; Marais, E.; Gallay, N.; Langonne, A.; Delorme, B.; Herault, O.; Charbord, P.; Domenech, J. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells, 2007, 25(7), 1737-1745.
45. Chamberlain, G.; Fox, J.; Ashton, B.; Middleton, J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells, 2007, 25(11), 2739-2749.
46. Tomchuck, S.L.; Zwezdaryk, K.J.; Coffelt, S.B.; Waterman, R.S.; Danka, E.S.; Scandurro, A. B. Toll-Like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells, 2008, 26(1), 99-107.
47. Lüttichau, I.V.; Notohamiprodjo, M.; Wechselberger, A.; Peters, C; Henger, A.; Seliger, C; Djafarzadeh, R.; Huss, R.; Nelson, P. J. Human adult CD34-progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Stem Cells Dev., 2005, 14(3), 329-336.
48. Honczarenko, M.; Le, Y.; Swierkowski, M.; Ghiran, I.; Glodek, A.M.; Silberstein, L. E. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells, 2006, 24(4), 1030-1041.
49. Sordi, V.; Malosio, M.L.; Marchesi, F.; Mercalli, A.; Melzi, R.; Giordano, T.; Belmonte, N.; Ferrari, G.; Leone, B.E.; Bertuzzi, F. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood, 2005, 106(2), 419-427.
50. Kemp, K.C.; Hows, J.; Donaldson, C. Bone marrow-derived mesenchymal stem cells. Leuk. Lymphoma, 2005, 46(11), 1531-1544.
51. Scadden, D. T. The stem-cell niche as an entity of action. Nature, 2006, 441(7097), 1075-1079.
52. Rattigan, Y.; Hsu, J.M.; Mishra, P.J.; Glod, J.; Banerjee, D. Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. Exp. Cell Res., 2010, 316(20), 3417-3424.
53. Uchibori, R.; Tsukahara, T.; Mizuguchi, H.; Saga, Y.; Urabe, M.; Mizukami, H.; Kume, A.; Ozawa, K. NF-kappaB activity regulates mesenchymal stem cell accumulation at tumor sites. Cancer Res., 2013, 73(1), 364-372.
54. Teo, G.S.; Ankrum, J.A.; Martinelli, R.; Boetto, S.E.; Simms, K.; Sciuto, T.E.; Dvorak, A.M.; Karp, J.M.; Carman, C. V. Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-alpha-activated endothelial cells via both leukocyte-like and novel mechanisms. Stem Cells, 2012, 30(11), 2472-2486.
55. Shi, M.; Li, J.; Liao, L.; Chen, B.; Li, B.; Chen, L.; Jia, H.; Zhao, R. C. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica, 2007, 92(7), 897-904.
56. Senst, C; Nazari-Shafti, T.; Kruger, S.; Zu Bentrup, K.H.; Dupin, C.L.; Chaffin, A.E.; Srivastav, S.K.; Wörner, P.M.; Abdel-Mageed, A.B.; Alt, E. U. Prospective dual role of mesenchymal stem cells in breast tumor microenvironment. Breast Cancer Res. Treat., 2013, 137(1), 69-79.
57. Liu, S.; Ginestier, C; Ou, S.J.; Clouthier, S.G.; Patel, S.H.; Monville, F.; Korkaya, H.; Heath, A.; Dutcher, J.; Kleer, C.G. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res., 2011, 71(2), 614-624.
58. Chaturvedi, P.; Gilkes, D.M.; Wong, C. C.L.; Luo, W.; Zhang, H.; Wei, H.; Takano, N.; Schito, L.; Levchenko, A.; Semenza, G. L. Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. J. Clin. Invest., 2013, 123(1), 189-205.
59. Gilkes, D.M.; Bajpai, S.; Chaturvedi, P.; Wirtz, D.; Semenza, G. L. Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts. J. Biol. Chem., 2013, 288(15), 10819-10829.
60. Coffelt, S.B.; Marini, F.C.; Watson, K.; Zwezdaryk, K.J.; Dembinski, J.L.; LaMarca, H.L.; Tomchuck, S.L.; Zu Bentrup, K.H.; Danka, E.S.; Henkle, S. L. The proinflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. PNAS, 2009, 106(10), 3806-3811.
61. Ip, J.E.; Wu, Y.; Huang, J.; Zhang, L.; Pratt, R.E.; Dzau, V. J. Mesenchymal stem cells use integrin β1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol. Biol. Cell, 2007, 18(8), 2873-2882.
62. Rüster, B.; Göttig, S.; Ludwig, R.J.; Bistrian, R.; Müller, S.; Seifried, E.; Gille, J.; Henschler, R. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood, 2006, 108(12), 3938-3944.
63. Wang, J.; Ma, D.; Li, Y.; Yang, Y.; Hu, X.; Zhang, W.; Fang, Q. Targeted delivery of CYP2E1 recombinant adenovirus to malignant melanoma by bone marrow-derived mesenchymal stem cells as vehicles. Anti-cancer Drugs, 2014, 25(3), 303-314.
64. Ahn, J.O.; Coh, Y.R.; Lee, H.W.; Shin, I.S.; Kang, S.K.; Youn, H. Y. Human adipose tissue-derived mesenchymal stem cells inhibit melanoma growth in vitro and in vivo. Anticancer Res., 2015, 35(1), 159-168.
65. Zhang, T.Y.; Huang, B.; Wu, H.B.; Wu, J.H.; Li, L.M.; Li, Y.X.; Hu, Y.L.; Han, M.; Shen, Y.Q.; Tabata, Y.; Gao, J. Q. Synergistic effects of co-administration of suicide gene expressing mesenchymal stem cells and prodrug-encapsulated liposome on aggressive lung melanoma metastases in mice. J. Control Release, 2015, 209, 260-271.
66. Zhong, Y.; Xu, J.; Deng, M.; Liu, B.; Zhang, F.; Yuan, Y.; Yang, X.; Xu, R. Generation of a human bone marrow-derived mesenchymal stem cell line expressing and secreting high levels of bioactive alpha-melanocyte-stimulating hormone. J. Biochem., 2013, 153(4), 371-379.
67. Fritz, V.; Jorgensen, C. Mesenchymal stem cells: an emerging tool for cancer targeting and therapy. Curr. Stem Cell Res. Ther, 2008, 3(1), 32-42.
68. Nakamura, K.; Ito, Y.; Kawano, Y.; Kurozumi, K.; Kobune, M.; Tsuda, H.; Bizen, A.; Honmou, O.; Niitsu, Y.; Hamada, H. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther., 2004, 11 (14), 1155-1164.
69. Duan, X.; Guan, H.; Cao, Y.; Kleinerman, E. S. Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. Cancer, 2009, 115(1), 13-22.
70. Gao, P.; Ding, Q.; Wu, Z.; Jiang, H.; Fang, Z. Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett., 2010, 290(2), 157-166.
71. Xu, G.; Jiang, X.D.; Xu, Y.; Zhang, J.; Huang, F.H.; Chen, Z.Z.; Zhou, D.X.; Shang, J.H.; Zou, Y.X.; Cai, Y.Q. Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats. Cell Biol. Int., 2009, 33(4), 466-474.
72. Kanehira, M.; Xin, H.; Hoshino, K.; Maemondo, M.; Mizuguchi, H.; Hayakawa, T.; Matsumoto, K.; Nakamura, T.; Nukiwa, T.; Saijo, Y. Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Cancer Gene Ther., 2007, 14(11), 894-903.
73. Ren, C.; Kumar, S.; Chanda, D.; Kallman, L.; Chen, J.; Mountz, J.D.; Ponnazhagan, S. Cancer gene therapy using mesenchymal stem cells expressing interferon-β in a mouse prostate cancer lung metastasis model. Gene Ther., 2008, 15(21), 1446-1453.
74. Studeny, M.; Marini, F.C.; Champlin, R.E.; Zompetta, C; Fidler, I.J.; Andreeff, M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res., 2002, 62(13), 3603-3608.
75. Li, X.; Lu, Y.; Huang, W.; Xu, H.; Chen, X.; Geng, Q.; Fan, H.; Tan, Y.; Xue, G.; Jiang, X. In vitro effect of adenovirus-mediated human Gamma Interferon gene transfer into human mesenchymal stem cells for chronic myelogenous leukemia. Hematol. Onco., 2006, 24(3), 151-158.
76. Xin, H.; Kanehira, M.; Mizuguchi, H.; Hayakawa, T.; Kikuchi, T.; Nukiwa, T.; Saijo, Y. Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells, 2007, 25(7), 1618-1626.
77. Hu, M.; Yang, J.L.; Teng, H.; Jia, Y.Q.; Wang, R.; Zhang, X.W.; Wu, Y.; Luo, Y.; Chen, X.C.; Zhang, R.; Tian, L.; Zhao, X.; Wei, Y. Q. Anti-angiogenesis therapy based on the bone marrow-derived stromal cells genetically engineered to express sFlt-1 in mouse tumor model. BMC Cancer, 2008, 8, 306.
78. Xiang, J.; Tang, J.; Song, C; Yang, Z.; Hirst, D.G.; Zheng, Q.J.; Li, G. Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma. Cytotherapy, 2009, 11(5), 516-526.
79. Uchibori, R.; Okada, T.; Ito, T.; Urabe, M.; Mizukami, H.; Kume, A.; Ozawa, K. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J. Gene Med., 2009, 11(5), 373-381.
80. Li, L.; Guan, Y.; Liu, H.; Hao, N.; Liu, T.; Meng, X.; Fu, C; Li, Y.; Qu, Q.; Zhang, Y.; Ji, S.; Chen, L.; Chen, D.; Tang, F. Silica nanorattle-doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy. ACS Nano, 2011, 5(9), 7462-7470.
81. Loebinger, M.R.; Eddaoudi, A.; Davies, D.; Janes, S. M. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res., 2009, 69(10), 4134-4142.
82. Shah, K.; Tung, C.-H.; Breakefield, X.O.; Weissleder, R. In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. Mol. Ther., 2005, 11 (6), 926-931.
83. Stoff-Khalili, M.A.; Rivera, A.A.; Mathis, J.M.; Banerjee, N.S.; Moon, A.S.; Hess, A.; Rocconi, R.P.; Numnum, T.M.; Everts, M.; Chow, L. T. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res. Treat., 2007, 105(2), 157-167.
84. Choi, S.A.; Lee, J.Y.; Wang, K.C.; Phi, J.H.; Song, S.H.; Song, J.; Kim, S.K. Human adipose tissue-derived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas. EJC, 2012, 48(1), 129-137.
85. Kucerova, L.; Matuskova, M.; Pastorakova, A.; Tyciakova, S.; Jakubikova, J.; Bohovic, R.; Altanerova, V.; Altaner, C. Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J. Gene Med., 2008, 10(10), 1071-1082.
86. Chen, Q.; Cheng, P.; Song, N.; Yin, T.; He, H.; Yang, L.; Chen, X.; Wei, Y. Antitumor activity of placenta-derived mesenchymal stem cells producing pigment epithelium-derived factor in a mouse melanoma model. Oncol. Lett., 2012, 4(3), 413-418.
87. Ren, C; Kumar, S.; Chanda, D.; Chen, J.; Mountz, J.D.; Ponnazhagan, S. Therapeutic Potential of Mesenchymal Stem Cells Producing Interferon-β in a Mouse Melanoma Lung Metastasis Model. Stem Cells, 2008, 26(9), 2332-2338.
88. Kievit, E.; Bershad, E.; Ng, E.; Sethna, P.; Dev, I.; Lawrence, T.S.; Rehemtulla, A. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res., 1999, 59(7), 1417-1421.
89. Jonasch, E.; Haluska, F. G. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist, 2001, 6(1), 34-55.
90. Leaman, D.W.; Chawla-Sarkar, M.; Jacobs, B.; Vyas, K.; Sun, Y.; Ozdemir, A.; Yi, T.; Williams, B.R.; Borden, E. C. Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-β compared with IFN-β 2. J. Interferon Cytokine Res., 2003, 23(12), 745-756.
91. Qin, X.-Q.; Tao, N.; Dergay, A.; Moy, P.; Fawell, S.; Davis, A.; Wilson, J.M.; Barsoum, J. Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. PNAS, 1998, 95(24), 14411-14416.
92. Deans,R.J.; Moseley, A.B. Mesenchymal stem cells: biology and potential clinical uses. Exp. Hematol., 2000, 28(8), 875-884.
93. Jo, A.; Hw, L.; Kw, S.; Sk, K.; Jc, R. Anti-tumor effect of adipose tissue derived-mesenchymal stem cells expressing interferon-β and treatment with cisplatin in a xenograft mouse model for canine melanoma, PLoS One, 2013, 8(9), e74897.
94. Dawson, D.; Volpert, O.; Gillis, P.; Crawford, S.; Xu, H.-J.; Benedict, W.; Bouck, N. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science, 1999, 285(5425), 245-248.
95. Elayappan, B.; Ravinarayannan, H.; Pasha, S. P. B.S.; Lee, K.-j.; Gurunathan, S. RETRACTED ARTICLE: PEDF inhibits VEGF-and EPO-induced angiogenesis in retinal endothelial cells through interruption of PI3K/Akt phosphorylation. Angiogenesis, 2009, 12(4), 313-324.
96. Bahrambeigi, V.; Ahmadi, N.; Moisyadi, S.; Urschitz, J.; Salehi, R.; Haghjooy Javanmard, S. PhiC31/PiggyBac modified stromal stem cells: effect of interferon gamma and/or tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) on murine melanoma. Mol. Cancer, 2014, 13, 255.